Skip To Content

Thought leadership on the clinical impact on workers' compensation and auto no-fault.

Recent blog posts

January 16, 2020
The U.S. Food and Drug Administration (FDA) has approved a new medication to treat acute (immediate) migraine with or without aura (often described as a visual disturbance such as flashing lights) in adults. Read more...
December 17, 2019 · Clinical Connection team
On December 19, 2019, the U.S. Food and Drug Administration (FDA) issued a warning that patients with certain respiratory risk factors who are using gabapentin (Neurontin®, Gralise®, Horizant®) or pregabalin (Lyrica®, Lyrica® CR) may experience serious breathing difficulties. Read more...
October 29, 2019
The U.S. Food and Drug Administration (FDA) reports that sales for the abuse-deterrent opioid analgesic, Embeda® (morphine sulfate and naltrexone extended-release capsules), manufactured by Pfizer Pharmaceuticals, will cease on November 15, 2019. Read more...
October 22, 2019 · Clinical Connection team
What you need to know about the Zantac and generic ranitidine recalls Read more...
August 30, 2019 · Clinical Connection team
On August 15, 2019, the U.S. Food and Drug Administration (FDA) announced that Pfizer Inc. issued a voluntary recall for two lots of Relpax® (eletriptan) 40 mg tablets to the patient level. Read more...
August 19, 2019 · Optum for Workers' Compensation
On September 18, 2019, Novartis announced it is stopping the distribution of its Sandoz division’s ranitidine, generic for Zantac®, until further notice. Read more...
August 06, 2019 · Clinical Connection team
The New York State Workers Compensation Board (WCB) has released information on how to access and use the Drug Formulary Prior Authorization System. Read more...
<< Previous      Next >>
Page 2 of 4

Subscribe today to receive our latest blogs, articles and more.

Subscribe now button

Download the latest
Pharmacy Resource Guide

Pharmacy Resource Guide